

TUPL01 Plenary Session

Plenary Session

Venue: Le Grand Amphithéâtre

Time: 08:45-10:30

Co-Chairs: Lambert Grijns, Ministry of Foreign Affairs, Netherlands
Françoise Barré-Sinoussi, Institut Pasteur, France

Award Presentation: Collaborative Initiative for Paediatric HIV Education and Research (CIPHER) Grant and Fellowship Programmes

L.Bekker, Desmond Tutu HIV Centre, South Africa

HIV restriction factors: from bench to bedside

P.Bieniasz, Rockefeller University, United States

Economic incentives for HIV prevention in Latin America

S.Sosa-Rubi, National Health Institute, Mexico

What will it take to end paediatric HIV: the emergency plan

N.Sam-Agudu, Institute of Human Virology, Nigeria, Nigeria

TUWS01 Prepping Men Who Have Sex with Men for Better Health Outcomes: A Conversation between Healthcare Providers and Their Clients

Workshop

Venue: Room 242

Time: 11:00-12:30

Co-Facilitators: Raoul Fransen Dos Santos, International Civil Society Support, Netherlands
Eric Paul Leue, Free Speech Coalition, United States

This workshop covers current hot topics around HIV prevention for men who have sex with men: PrEP, dating apps, 'chem sex', and condomless sex (barebacking). Each of these topic areas will be spotlighted in separate conversations between healthcare providers and their clients, closing with a question to the audience who can voice their opinion via a polling device (stand-up microphones will be provided for a representative from the audience to explain their choice). Target audience of this workshop are men who have sex with men, their service providers, as well as policy-makers and HIV prevention programme implementers. Participants will get to know the latest methods and tools of HIV prevention for men who have sex with men. They will also develop a better understanding of the realities of men who have sex with men and how to integrate these realities into more targeted and effective HIV prevention programming.

PrEP and Proud: Film

I.AIDS Society, Switzerland

Welcome and introductions

E.Leue, Free Speech Coalition, United States; R.Dos Santos, International Civil Society Support, Netherlands

Conversation 1: PrEP – uptake and adherence

PrEP uptake and adherence: experiences from Thailand PrEP programs

N.Phanuphak, Thai Red Cross AIDS Research Centre, Thailand

To PrEP or Not to PrEP: A Dilemma Through My Lens

P.Seekaw, Thai Red Cross AIDS Research Centre, Thailand

#Transmit Love. Engaging gay men in Chicago around PrEP

J.Pickett, AIDS Foundation of Chicago, United States

Getting it online

G.Mi, Blued, China

Conversation 2: condoms, lube, barebacking: between pleasure and risk reduction

Perspectives from the men who have sex with men community in Asia on sexual pleasure and risk reduction

M.Poonkasetwattana, Asia Pacific Coalition on Male Sexual Health (APCOM), Thailand

PrEP and condoms: how to promote and implement combination prevention for men who have sex with men

R.Baggaley, World Health Organization (WHO), Switzerland

Conversation 3: chemsex: its compatibility with PrEP and ART and impact on treatment adherence

On recreational drug use and sexual behaviour in men who have sex with men

N.Nwokolo, Chelsea and Westminster Hospital NHS Foundation Trust, United Kingdom

Community perspectives on chemsex

P.Steinberg, London HIV Prevention Programme (LHPP), United Kingdom

Intervention from the floor

G.Cairns, National AIDS Manual (NAM), United Kingdom

TUAC01 Updates from PrEP Clinical Trials

Oral Abstract Session

Venue: Blue Amphitheater

Time: 11:00-12:30

Co-Chairs: Robert Grant, Gladstone Institutes/UCSF, United States
Flavia Kiweewa Matovu, Makerere University, Uganda

Long-term follow-up of PROUD: evidence for high continued HIV exposure and durable effectiveness of PrEP

E. White, D. Dunn, R. Gilson, A. Sullivan, A. Clarke, I. Reeves, G. Schembri, N. Mackie, C. Dewsnap, C. Lacey, V. Apea, M. Brady, J. Fox, S. Taylor, J. Rooney, M. Gafos, O.N. Gill, S. McCormack, PROUD Study Group, United Kingdom

On-demand PrEP with TDF/FTC remains highly effective among MSM with infrequent sexual intercourse: a sub-study of the ANRS IPERGAY trial

G. Antoni, C. Tremblay, I. Charreau, E. Cua, D. Rojas-Castro, N. Hall, J. Chas, T. Huleux, B. Spire, C. Capitant, L. Cotte, L. Meyer, J.-M. Molina, ANRS IPERGAY Study Group, France

An open-label multiple dose phase 1 assessment of long-acting rilpivirine

I. McGowan, C.S. Dezzutti, A. Siegel, J. Engstrom, C. Shetler, N. Richardson-Harman, K. Abebe, D. Back, L. Else, D. Egan, S. Khoo, P.E. Williams, R.M. Brand, B.A. Chen, S.L. Achilles, R.D. Cranston, United States

Impact of microbiota on female genital tissue and plasma concentrations of dapivirine

S. Hillier, L. Meyn, K. Bunge, M. Austin, B. Moncla, C. Dezzutti, B. Devlin, M. Marzinke, C. Hendrix, L. Rohan, United States

Experiences and perceptions of PrEP among gay and other men who sex with men (MSM) using PrEP in the PROUD study in England

M. Gafos, W. Nutland, S. Wayal, G. Bell, M. Rayment, C. Rae, S. McCormack, R. Horne, United Kingdom

Safety, tolerability and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected women and men: HPTN 077

R. Landovitz, S. Li, B. Grinsztejn, H. Dawood, A. Liu, M. Magnus, M. Hosseinipour, R. Panchia, L. Cottle, G. Chau, P. Richardson, M. Marzinke, C. Hendrix, B. Tolley, A. Adeyeye, D. Burns, A. Rinehart, D. Margolis, M. McCauley, J. Eron, United States

TUAC02 Prevention and Adolescents

Oral Abstract Session

Venue: Havana Amphitheater

Time: 11:00-12:30

Co-Chairs: Nyaradzo Mavis Mgodi, University of Zimbabwe, Zimbabwe

Murli Purswani, Bronx-Lebanon Hospital Center, United States

High uptake of community-based HIV testing by adolescent girls and young women aged 15-24: implications and synergies for PrEP roll out?

A. Medina-Marino, A. Mumbauer, T. Farirai, L.-G. Bekker, S. Johnson, N. Nkhwashu
South Africa

Finding the right target population for PrEP: the cost-effectiveness of pre-exposure prophylaxis provision to female and male adolescents and young women in South Africa

G. Meyer-Rath, L. Jamieson, L. Johnson
United States

State-level school-based sex education policies on sexual orientation are associated with changes in teaching about HIV prevention

A. Grosso, D. Bermudez, M.A. Chiasson
United States

Potential for HIV transmission among adolescents and young adults receiving antiretroviral therapy

S. Wood, N. Dowshen, C. Gowda, S. Lee, S. Ratcliffe, R. Gross
United States

HIV and HSV-2 risk among young women in age-disparate partnerships: evidence from KwaZulu-Natal, South Africa

B. Maughan-Brown, G. George, S. Beckett, M. Evans, C. Cawood, D. Khanyile, L. Lewis, A. Kharsany
South Africa

Safety and acceptability trial of the dapivirine vaginal ring in U.S. adolescents

K. Bunge, L. Levy, D. Szydlo, J. Zhang, A. Gaur, D. Reirden, K. Mayer, D. Futterman, C. Hoesley, S. Hillier, M. Marzinke, C. Dezzutti, C. Wilson, L. Soto-Torres, B. Kapogiannis, A. Nel, K. Squires, MTN-023/IPM 030 Protocol Team
United States

Pluspills: an open label, safety and feasibility study of oral pre-exposure prophylaxis (PrEP) in 15-19 year old adolescents in two sites in South Africa

K. Gill, J. Dietrich, G. Gray, T. Pidwell, F. Kayamba, T. Bennie, L. Myer, L. Johnson, H. Spiegel, C. Slack, V. Elharrar, A. Strode, J. Rooney, L.-G. Bekker
South Africa

TUAC03 Hitting the First 90 Target: Lessons from Population-based Surveys

Oral Abstract Session

Venue: Maillot Room

Time: 11:00-12:30

Co-Chairs: James Hakim, University of Zimbabwe, Zimbabwe
Virginie Supervie, Institut national de la santé et de la recherche médicale (Inserm), France

Findings from the 2016 Zambia Population-based HIV Impact Assessment (ZAMPHIA): HIV prevalence, incidence and progress towards the 90-90-90 goals

D.T. Barradas, S. Gupta, C. Moyo, K. Sachathep, K. Dzekedzeke, T. Nkumbula, D.B. Williams, H. Patel, T. Dobbs, C. Nakazwe, W. Kasongo, H. Cai, S. Kamocho, C.B. Ndongmo, K. Hageman, M.A. Riggs, ZAMPHIA Study Team
Zambia

Correlates of being outside the 90-90-90 cascade among adults ages 15-64 years in Zimbabwe

A. Hakim, E. Radin, L. Ruangtragool, A. Herman-Roloff, N. Ahmed, G. Musuka, H. Dube, M. Mhangara, L. Gwanzura, S. Munyati, E. Gonese, A. Nwankwo-Igomu, H. Patel, K. Sleeman, S. Kinchen, J. Justman, B.A. Tippet-Barr, ZIMPHIA Survey Group
United States

90-90-90 targets in HIV-positive women using results from MPHIA: a Malawi success story

N. Wadonda-Kabondo, C. West, R. Nyirenda, F. Chimbwandira, S. Nkoka, A. Voetsch, T. Dobbs, G. Chipungu, I. Chirwa, M. Blackson, G. Sundeep, E. Radin, MPHIA Study Team
Malawi

Children living with HIV in Malawi: first survey-based measurement of national pediatric HIV prevalence and viral suppression

S. Jonnalagadda, G. Bello, S. Suzue, J. Burnett, E. Radin, K. Brown, J. Cuervo-Rojas, F. Ogollah, E. Kim, D. Payne, H. Patel, K. Sleeman, S. Hrapcak, A. Voetsch, Malawi Population-based HIV Impact Assessment Study Group

United States

Estimating HIV incidence and the undiagnosed HIV population in the European Union / European economic area

A. van Sighem, A. Pharris, C. Quinten, T. Noori, A.J. Amato-Gauci, and the ECDC HIV/AIDS Surveillance and Dublin Declaration Networks
Netherlands

TUAA01 The Wrestling Match: Virus Versus Immune Cells

Oral Abstract Session

Venue: Room 241

Time: 11:00-12:30

Co-Chairs: Mirko Paiardini, Emory University School of Medicine, United States
Sarah Palmer, The University of Sydney, Australia

Evaluation of memory CD8+ T cell responses in individuals initiating cART during hyperacute HIV-1 infection

T.P. Nkosi, K. Pretorius, N. Mewalal, T. Ndung'u, Z. Ndhlovu
South Africa

Early anti-SIV CD8+ T cell antiviral activity is associated with durable elite control of SIV infection in macaques carrying or not protective MHC alleles: the ANRS SIC study

C. Passaes, A. Millet, V. Madelain, V. Monceaux, A. David, P. Versmisse, N. Sylla, M. Ploquin, D. Duffy, C. Joubert, A. Blancher, N. Bosquet, R. Le Grand, G. Pancino, M. Muller-Trutwin, J. Guedj, V. Avettand-Fenoel, C. Rouzioux, B. Vaslin, A. Sáez-Cirión
France

CD8+ T cell depletion leads to a different profile of SIV viral decay under integrase inhibitor monotherapy

B. Policicchio, E. Fabian Cardozo, C. Xu, D. Ma, T. He, K. Raehtz, R. Sivinandham, A. Kleinman, G. Haret-Richter, T. Dunsmore, C. Apetrel, I. Pandrea, R. Ribeiro
United States

Memory-like NK cells exploit innate priming and alternative signaling mechanisms to enhance function and mobilize at HIV/SIV mucosal portals of entry

S. Shah, C. Manickam, A. Jimenez, R.K. Reeves
United States

The human penis is an immunologically active tissue: a preliminary study on the development of an HIV vaccine

A. Sennepin, F. Real, M. Duvivier, Y. Ganor, S. Henry, D. Damotte, M. Revol, S. Cristofari, M. Bomsel
France

Efficacy of epithelial stem cell-based AIDS vaccine to induce mucosal immune responses offering protection against SIV challenge in macaques

M.-C.E. Gauduin, R. White, J. Garcia, P. Kozlowski, P. Blancou, P. Frost
United States

TUBS01 Primary HIV Infection and Early Treatment

Bridging Session

Venue: Bordeaux Amphitheater

Time: 11:00-12:30

Co-Chairs: Asier Sáez-Cirión, Institut Pasteur, France
Jean-Pierre Routy, McGill University Health Centre, Canada

This session provides insights into the early events following HIV primary infection and how treatment initiation at this stage may promote control of HIV and prevent the establishment of chronic infection. The latest discoveries in the field are explored as well as how these can help us develop strategies to improve the condition of newly HIV-infected patients. This session, tailored to scientists and clinicians concerned with this fundamental phase of HIV infection, and the potential outcome of interventions, furthers the discussion around the improvement of primary-infection diagnosis.

Introduction

Historical perspective: primary HIV infection as a critical window of opportunity

C.Rouzioux, Université Paris Descartes, France

New insights into the immune response and viral reservoir during PHI

L.Trautmann, Walter Reed Army Institute of Research (WRAIR), United States

Which treatment during PHI for which results?

J.Frater, Oxford University, United Kingdom

Evolution of recently transmitted viruses and consequences for the host

C.Williamson, University of Cape Town, South Africa

The future of early diagnosis and intervention during PHI

J.Ananworanich, US Military HIV Research Program (MHRP), United States

Questions and answers

Closing remarks

TUSY01 Differentiated Service Delivery and Care: Key Considerations for Successful Scale-up

Symposia Session

Venue: Le Grand Amphithéâtre

Time: 11:00-12:30

Co-Chairs: Anna Grimsrud, International AIDS Society (IAS), South Africa
Bactrin Killingo, International Treatment Preparedness Coalition (ITPC), Kenya

A panel of Ministries of Health representatives, researchers, civil society, policy makers and implementers describe the current state of affairs related to the uptake and implementation of the differentiated service delivery and care policies and report back on a meeting held in November 2016 by WHO, IAS and partners to adapt the Decision Framework to specific populations – children, adolescents, pregnant and breastfeeding women and key populations (people who inject drugs, sex workers, men who have sex with men, transgender people and people in prison and closed settings). The Key considerations are described and the evidence needed to expand and learn from these models for all populations.

The programme uses, as its guiding documents, the products that WHO, IAS and other partners launched in a satellite on Sunday 23 July (Differentiated Care from Testing to Suppression: Are We at the Tipping Point?):

Key considerations for differentiated antiretroviral therapy delivery for specific populations: children, adolescents, pregnant and breastfeeding women and key populations. Differentiated Care for HIV: A Decision framework for antiretroviral therapy delivery for children, adolescents and pregnant and breastfeeding women

Introduction

Differentiated service delivery for children, adolescents and pregnant and breastfeeding women: key considerations from the policy perspective

M.Doherty, World Health Organization (WHO), Switzerland

Differentiated service delivery for adolescents and young people: youth perspective

P.Ndlovu, Wits Reproductive Health and HIV Institute (WRHI), South Africa

Differentiated service delivery for key populations: key considerations from a policy perspective

V.MacDonald, World Health Organization (WHO), Switzerland

Differentiated service delivery for key populations: key population perspective

O.Mellouk, International Treatment Preparedness Coalition (ITPC), Morocco

Differentiated service delivery in action: what is happening at country level?

T.Apollo, Zimbabwe Ministry of Health and Child Welfare, Zimbabwe

Panel discussion of differentiated care stakeholders

A.Fakoya, The Global Fund to Fight AIDS, Tuberculosis and Malaria, Switzerland; P.Ehrenkranz, Bill & Melinda Gates Foundation, United States

Closing remarks

TUSY02 Broadly Neutralizing Antibodies against HIV

Symposia Session

Venue: Room 251

Time: 11:00-12:30

Co-Chairs: Hugo Mouquet, Institut Pasteur, France
Olivier Schwartz, Institut Pasteur, France

The objective of this session is to learn about the latest developments on the use of broadly neutralizing antibodies against HIV. This session is addressed to scientists and clinicians concerned with the feasibility, applicability and effectiveness of broadly neutralizing antibodies to prevent HIV infection or establish long-term control of the virus replication. The audience is presented the latest discoveries in the field of HIV broadly neutralizing antibodies in both primates and humans, to highlight the challenges related to their use, as well as the opportunities and hopes these tools offer to the response to HIV.

Introduction

Determinants of bnAbs development in humans

R.Kouyos, University of Zurich, Switzerland

Translational development of PGT121 and PGDM1400

D.Barouch, Harvard Medical School, United States

bnAbs and partial control of cell-associated SHIV infection

S.Kent, The University of Melbourne, Australia

bnAbs to prevent mother to child transmission (MTCT)

L.Mofenson, Elizabeth Glaser Pediatric AIDS Foundation, United States

Questions and answers

Closing remarks

TUPDB02 Late Breaker Poster Discussion Session

Poster Discussion Session

Venue: Havana Amphitheater

Time: 13:00-14:00

Co-Chairs: Jürgen Rockstroh, University Hospital Bonn, Germany
Constance Delaunay, Saint-Louis Hospital, France

Phase 3 randomized, controlled clinical trial of bictegravir coformulated with FTC/TAF in a fixed-dose combination (B/F/TAF) vs dolutegravir (DTG) + F/TAF in treatment-naïve HIV-1 positive adults: week 48 results

P.E. Sax, A. Pozniak, J. Arribas, E. Koenig, E. DeJesus, H.-J. Stellbrink, A. Antinori, K. Workowski, J. Slim, J. Reynes, W. Garner, D. Sengupta, H. Martin, E. Quirk, A. Cheng
United States

Single doses as low as 0.5 mg of the novel NRTTI MK-8591 suppress HIV for at least seven days

R.P. Matthews, D. Schürmann, D.J. Rudd, V. Levine, S. Fox-Bosetti, S. Zhang, M. Robberechts, A. Huser, D.J. Hazuda, M. Iwamoto, J.A. Grobler
United States

Pharmacokinetics, pharmacodynamics and pharmacogenomics of efavirenz 400mg once-daily during pregnancy and postpartum

M. Lamorde, X. Wang, M. Neary, E. Bisdomini, S. Nakalema, P. Byakika, J. Mukonzo, W. Khan, A. Owen, M. McClure, M. Boffito

United Kingdom

Universal sputum testing vs. symptom-based testing for tuberculosis (TB) in HIV-infected pregnant women: a cluster-randomized implementation trial in South Africa

N. Martinson, K. Motihaoleng, E. Variava, G. Barnes, P. Abraham, L. Lebina, S. Cohn, L. Moulton, N. Salazar-Austin, R. Chaisson
South Africa

Sub-study 202094 of SWORD 1 & SWORD 2: switch from TDF containing regimen to DTG+RPV improves bone mineral density and bone turnover markers over 48 weeks

G. McComsey, J. Gonzalez-Garcia, S. Lupo, J. De Wet, D. Parks, L. Kahl, B. Wynne, M. Gartland, K. Angelis, M. Cupo, K. Vandermeulen, M. Aboud
United States

Earlier treatment and lower mortality in infants initiating antiretroviral therapy at < 12 weeks of age in South Africa: The International epidemiologic Databases to Evaluate AIDS Southern Africa (IeDEA-SA) Collaboration

V. Iyuu, K. Technau, B. Eley, H. Rabie, A. Boulle, G. Fatti, F. Tanser, R. Wood, L. Fairlie, M.-A. Davies
South Africa

TUPDD01 The Missing Men

Poster Discussion Session

Venue: Mailloir Room

Time: 13:00-14:00

Co-Chairs: Helen Ayles, Zimbart, Zimbabwe
Matthew Mimiaga, Brown University, United States

Poor retention and care-related sex disparities among youth living with HIV in rural Mozambique

A. Ahonkhai, M. Aliyu, C. Audet, M. Simmons, G. Claquin, S. Vermund, W. Wester
Mozambique

Gender age considerations and likelihood of viral load suppression at sub-national level in five counties, Kenya

S. Muga, J. Onyalo, M. Obuya, P. Njoka, R. Kithuka, C. Komen, L. Muyumbu, G. Obanyi, E. Ashiono, C. Muturi, R. Odhiambo, P. Mwarogo, N. Njuguna
Kenya

Tanzanian men more successful than women in referring sexual partners to HIV testing via partner notification

K. Curran, M. Plotkin, C. Kahabuka, A. Christensen, R. Kisendi, W. Maokola, M. Betron, K. Grabbe, M. Drake, E. Mlanga, V. Wong
United States

Male engagement strategies effective in improving Option B+ retention in rural Mozambique

C. Audet, E. Graves, M. Bravo, M.F.S. Alvim, A. Green, Y.M. Chire
United States

Using traditional techniques to increase uptake of male circumcision and HIV testing and counselling services of males ages 15-29 through Lihawu Male Mentoring Camp

R. Britch, T. Churchyard, M. Sibanda
Swaziland

Men are absent across the HIV continuum of care in a rural area of southern Mozambique

L. Fuente-Soro, E. López-Varela, O. J. Augusto, C. Sacoora, A. Nhacolo, E. Bernardo, E. Karajeane, P. Vaz, D. Nanihe
Mozambique

TUPDB01 HIV Reservoirs: Ups and Downs

Poster Discussion Session

Venue: Room 241

Time: 13:00-14:00

Co-Chairs: Anne-Geneviève Marcelin, Hôpital Pitié-Salpêtrière, France
Caroline Tiemessen, National Institute for Communicable Diseases (NICD), South Africa

Dynamics of HIV-1 DNA in children over long-term sustained viral suppression: impact of the time of infection at viral control on reservoir size

M. Moragas, M. Distefano, D. Mecikovsky, S. Arazi Caillaud, R. Bologna, P. Aulicino, A. Mangano
Argentina

Impact of T cell homeostasis and thymic output on the seeding of the HIV reservoir in infants

M. Massanella, J. Ananworanich, L. Leyre, T. Jupimai, P. Sawangsinth, M. de Souza, P. Suntarattiwong, P. Kosalarksa, T. Puthanakit, N. Chomont, HIVNAT209 and HIVNAT194 study groups
Canada

Prolonged HIV-1 remission and viral rebound in an individual treated during hyperacute infection

T. Henrich, H. Hatano, A. Hill, O. Bacon, M. Kearney, J. Blankson, S. Cohen, M. Abdel Mohsen, R. Fromentin, J. Spindler, K. Metcalf-Pate, R. Siliciano, D. Richman, N. Chomont, J. Siliciano, J. Mellors, T. Liegler, S. Deeks
United States

HIV RNA persists in rectal tissue despite rapid virologic suppression in blood plasma with dolutegravir-based combination antiretroviral therapy in treatment-naïve patients

C. Lahiri, N. Brown, H. Chien, A. Vunnava, K. Ryan, E. Acosta, A. Sheth, J. Ingersoll, I. Ofotokun
United States

Viral rebound in semen after treatment interruption in a HIV therapeutic vaccine double-blind trial (VRI02/ANRS149-LIGHT)

J. Ghosn, R. Palich, A. Chaillon, V. Boilet, M.-L. Néré, P. Delobel, F. Lutch, O. Bouchaud, J.-M. Molina, M.-L. Chaix, C. Delaugerre, V. Rieux, R. Thiebaut, Y. Lévy, J.-D. Lelièvre
France

Viral and host characteristics of a child with perinatal HIV-1 following a prolonged period after ART cessation in the CHER trial

A. Violari, M. Cotton, L. Kuhn, D. Schramm, M. Paximadis, S. Loubser, S. Shalekoff, B. da Costa Dias, K. Otjombe, A. Liberty, J. McIntyre, A. Babiker, D. Gibb, C. Tiemessen
South Africa

TUPDC01 TRANScending Barriers for Prevention

Poster Discussion Session

Venue: Room 242

Time: 13:00-14:00

Co-Chairs: Yazdan Yazdanpanah, Groupe Hospitalier Bichat-Claude Bernard, France
Alicia Krüger, Ministry of Health, Brazil

Transgender women willingness to use PrEP in northeastern Brazil

F. Soares, I. Dourado, L. Magno, L.A. Vasconcelos da Silva, A. Nunn, PopTrans Study Group
Brazil

How are transwomen acquiring HIV? Insights from phylogenetic transmission clusters

H.-H.M. Truong, K. O'Keefe, S. Pipkin, T. Liegler, S. Scheer, W. McFarland
United States

Discrepancy between risky sexual behavior and perceived HIV risk among transgender women in community-based test and treat cohorts in Thailand

A.R. Ramautarsing, T. Nakpor, R. Janamuysook, S. Pengnonyang, J. Jantarapakde, D. Trachunthong, T. Sungsing, P. Rodbamrung, P. Mingkwanrungruangkit, W. Sirisakyot, S. Tongmuang, S. Jarupittaya, N. Mahachokchai, P. Yokchawee, S. Samalu, M. Uthakorn, W. Champa, P. Patpeerapong, S. Mills, S. Chareonying, P. Phanuphak, M. Cassell, R. Vannakit, N. Phanuphak
Thailand

Engaging transgender women of color in HIV prevention: findings from mixed methods community-based research

T. Poteat, M. Malik, A. Wirtz, E. Cooney
United States

Factors associated with HIV infection among transgender women in Cambodia: results from a national integrated biological and behavioral survey

S. Yi, S. Chhim, P. Chhoun, S. Tuot, P. Mun, K. Pal, C. Ngim
Cambodia

Prevalence and correlates of police harassment among transgender women in Jamaica: implications for HIV prevention and care

C.H. Logie, A. Lacombe-Duncan, K. Levermore, N. Jones, A. Neil, T. Ellis, Y. Wang, P.A. Newman
Canada

High level of retention and adherence at week 48 for MSM and TGW enrolled in the PrEP Brasil demonstration study

*B. Grinsztejn, B. Hoagland, R. Moreira, E. Kallas, J. Madruga, I. Leite, R. de Boni, P. Anderson, A. Liu, P. Luz, V. Veloso, PrEP Brasil Study Group
Brazil*

TUPDA01 Immunotherapy: Outsmarting the Virus

Poster Discussion Session

Venue: Room 251

Time: 13:00-14:00

Co-Chairs: Irini Sereti, National Institutes of Allergy and Infectious Diseases, United States
Nabila Seddiki, The Vaccine Research Institute / Université Paris-Est Créteil, France

Combined IL-21 and IFN α treatment limits residual inflammation and delays viral rebound in SIV-infected macaques

*L. Micci, J. Harper, S. Paganini, C. King, E. Ryan, F. Villinger, J. Lifson, M. Paillardini
United States*

Interleukin (IL)-27 induces HIV-resistance in T cells and dendritic cells via different mechanisms: identification of YB-1 and ANKRD22 as novel host dependency factors

*D. Poudyal, B. Sowrirajan, Q. Chen, J. Adelsberger, M. Bosche, J. Yang, H.C. Lane, T. Imamichi
United States*

Increased effector cytotoxic lymphocytes in lymph nodes of hetIL-15 treated macaques suggest potential to disrupt SIV/HIV reservoirs

*A. Valentin, E. Moysi, D.C. Watson, C. Petrovas, C. Bergamaschi, B.K. Felber, G.N. Pavlakis
United States*

The human IL-15 superagonist ALT-803 activates NK and memory T cells, reactivates latent SIV and drives SIV-specific CD8 $^{+}$ T cells into B cell follicles

*G. Webb, S. Li, J. Greene, J. Reed, J. Stanton, A. Legasse, B. Park, M. Axthelm, E. Jeng, H. Wong, J. Whitney, B. Jones, D. Nixon, P. Skinner, J. Sacha
United States*

Tissue factor pathway inhibitor Ixolaris improves disease outcome in progressive SIVsub-infected pigtail macaques

*T. He, M. Schechter, B. Andrade, G.H. Richter, B. Policicchio, K. Raehtz, E. Brocca-Cofano, C. Apetrei, R. Tracy, R. Ribeiro, I. Francischetti, I. Sereti, I. Pandrea
United States*

Engineering HIV immunity with a chimeric antigen receptor in the non-human primate model

*A. Zhen, C. Peterson, M. Carrillo, V. Rezek, M. Kamata, J. Zack, H.-P. Kiem, S. Kitchen
United States*

TUSS01 Translating Impact from AIDS for Global Health

Special Session

Venue: Le Grand Amphithéâtre

Time: 13:00-14:00

Chair: Jon Cohen, Science, United States

This session assesses the future of the HIV response in the context of an increasingly integrated global health and development agenda. Sustainable epidemic control is required to combat increasing concentration of the epidemic in key populations. Four decades into the battle with HIV/AIDS, there have been many lessons learnt from the HIV response as well as other global health efforts that could be used to champion future efforts that are more efficient, effective and require fewer resources. This session aims to discuss these lessons, as well as identify real threats to global health and the HIV response.

Introduction

J. Cohen, Science, United States

Panel discussion

M. Kazatchkine, UN Secretary-General Special Envoy on HIV/AIDS in Eastern Europe and Central Asia, Switzerland; D. Bix, The U.S. President's Emergency Plan for AIDS Relief (PEPFAR), United States; A. Kamarulzaman, University of Malaya, Malaysia; S. Aliyu, National Agency for the Control of AIDS (NACA), Nigeria

Address and Women, Girls and HIV Investigator's Prize

R. Goudou Coffie, Ministre de la Santé et de l'Hygiène Publique, Cote D'Ivoire

Closing remarks

TUWS02 Publish or Perish: How to Write and Submit a Research Manuscript

Workshop

Venue: Room 241

Time: 14:30-17:00

Co-Facilitators: Marlène Bras, Journal of the International AIDS Society, Switzerland
Elisa de Castro Alvarez, Journal of the International AIDS Society, Switzerland

Grasping the subtleties of manuscript writing can be a frustrating path, lined with rejected papers. Written guidelines cannot easily be translated into practice, but publishing is a critical part of a researcher's career. This interactive workshop seeks to build skills in scientific writing and provides practical information to support new and early-career HIV researchers in successfully submitting their manuscripts to peer-reviewed journals. By the end of the workshop, participants will know the key components of a scientific manuscript and would have completed short practical exercises. Participants also learn about the publication and peer-review processes and how to address ethical issues in scientific writing. The most common reasons why manuscripts are rejected are discussed, as well. Questions can be asked throughout the workshop. Hence, while targeted at less experienced authors, the workshop focuses on practical issues in scientific publishing, also of interest to more experienced researchers.

Introduction

M. Bras, Journal of the International AIDS Society, Switzerland

How to write a research manuscript

M. Bras, Journal of the International AIDS Society, Switzerland; E. de Castro Alvarez, Journal of the International AIDS Society, Switzerland

Choosing a journal and submitting a manuscript

K. Mayer, The Fenway Institute, United States

Editorial decision making and common reasons for rejection

K. Mayer, The Fenway Institute, United States

Responding to reviewers and revising a manuscript

K. Mayer, The Fenway Institute, United States

Publication ethics

K. Mayer, The Fenway Institute, United States

Q&A

D. Smith, UCSD, United States

TUWS03 Changing Landscapes, Changing Gears: Differentiated Service Delivery for Adolescents Living with HIV

Workshop

Venue: Room 242

Time: 14:30-17:00

Co-Facilitators: Carlo Oliveras, Adolescent HIV Treatment Coalition, Puerto Rico
Annette Sohn, amFAR, the Foundation for AIDS Research, Thailand

Worldwide, it is estimated that 1,8 million adolescents age 10-19 were living with HIV in 2015. HIV continues to be one of the leading causes of deaths among adolescents age 10-19, claiming 41,000 lives in 2015. And numbers of adolescents living with HIV (ALWH) will continue to rise at the projected rate of 250,000 new infections per year among adolescents age 15-19 between 2015 and 2020 and even more afterward if the response remains the same.

Adolescents are not adults at younger ages. They have distinctive developmental characteristics that need to be seriously taken into account while engaging with them in HIV programmes. This session addresses the particular needs of ALWH for services. The workshop is led and facilitated by young people and designed to accommodate policy makers, programme managers, service providers, community advocates and researchers. During the workshop, participants can learn more about the role of peers in providing psychosocial support, discuss the necessities of differentiated service provision for this special population, and hear from young people about what they want. Come prepared to interact as this session is highly participatory and will include a movie screening and online quiz.

Objectives:

- To deepen the understanding of participants about what is differentiated care for ALWH;
- To learn more about best practice examples of differentiated service delivery for ALWH; and
- To discuss what we know and what we don't going forward.

Welcome

Films

I.AIDS Society, , Switzerland

What is DSD for adolescents living with HIV?

C.Oliveras, Adolescent HIV Treatment Coalition, Puerto Rico; A.Sohn, amfAR, the Foundation for AIDS Research, Thailand

Changing landscape: the role of peers in providing psychosocial support and care to adolescents living with HIV

S.Mushonga, Africaid Zvandiri, Zimbabwe

As it happens: best practices in differentiated service delivery for adolescents living with HIV in Brazil and South Africa

D.Callisto, Ministry of Health, Brazil; P.Ndlovu, Wits Reproductive Health and HIV Institute (WRHI), South Africa

Break

The voice from within: what makes adolescents living with HIV engage (or not) with HIV services?

L.Benjamin, Tanzania Youth Alliance (TAYOA), United Republic of Tanzania; G.Yadav, Y+, India

Closing remarks

TUWS04 New Technologies

Workshop

Venue: Room 251

Time: 14:30-17:00

Co-Facilitators: Brigitte Autran, Université Pierre et Marie Curie, France
Steven Bosinger, Emory University, United States

This workshop, aimed at researchers and scientists concerned with technological developments and applications necessary to decipher the precise mechanisms underlying HIV pathogenesis, focuses on NEXGEN technologies applied to HIV basic science. Participants can expect to learn about state-of-the-art technological advances related to the study of single cells and molecules, the imaging of the immune response and the virus, deep sequencing of the virus and systems biology, and application of iPSC approaches.

Introduction

Study of single cells and molecules

P.Chattopadhyay, National Institutes of Health (NIH), United States

Systems biology: omics

R.Sekaly, Vaccine & Gene Therapy Institute of Florida, United States

Imaging of immunity (histo-cytometry): applications in human research

C.Petrovas, National Institutes of Health (NIH), United States

High resolution functional and structural mapping of the HIV-1 genome

R.Marquet, Université de Strasbourg, France

iPSC technology

S.Kaneko, Kyoto University, Japan

Deep sequencing of the virus

B.Keele, Leidos Biomedical Research, Inc, United States

Closing remarks

TUAB01 Antiretroviral Therapy - ART: Season Two

Oral Abstract Session

Venue: Le Grand Amphithéâtre

Time: 14:30-16:00

Co-Chairs: Serge Eholie, University Félix Houphouët-Boigny, Cote D'Ivoire
Monica Gandhi, University of California, United States

Efficacy and safety of switching from boosted-protease inhibitor plus emtricitabine/tenofovir disoproxil fumarate regimens to the single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in virologically-suppressed, HIV-1-infected adults through 24 weeks: EMERALD study

J.-M. Molina, J. Gallant, C. Orkin, E. Negredo, L. Bhatti, J. Gathe, E. Van Landuyt, E. Lathouwers, V. Hufkens, S. Vanveggel, M. Opsomer, France

Switching from a boosted protease inhibitor (PI/r) based regimen to a dolutegravir regimen in virologically suppressed patients with high cardiovascular risk or age =50 years is non-inferior and decreases lipids

J.M. Gatell, L. Assoumou, G. Moyle, L. Waters, E. Martinez, H.-J. Stellbrink, G. Guaraldi, S. de Wit, F. Raffi, A. Pozniak, NEAT022 Study Group, Spain

Efficacy of dual therapy with protease inhibitors plus lamivudine as maintenance treatment in HIV-positive patients on second-line in Africa: the ANRS 12286/MOBIDIP trial 96 weeks results

L. Ciuffi, S. Koulla Shiro, A. Sawadogo, C. T Ndour, S. Eymard-Duvernay, S. Izard, V. Le Moing, J. Zoungrana, R. Toby, C. Kouanfack, M. Mpoudi, N.F. Ngoum Gueye, M. Diallo, G. Bado, K. Toure Kane, A. Aghokeng, M. Peeters, J. Reynes, E. Delaporte, Cameroon

Fixed dose combination of doravirine/lamivudine/TDF is non-inferior to efavirenz/emtricitabine/TDF in treatment-naïve adults with HIV-1 infection: week 48 results of the Phase 3 DRIVE-AHEAD study

K.E. Squires, J.-M. Molina, P.E. Sax, W.-W. Wong, C. Orkin, O. Sussmann, D. Tutu, L. Lupinacci, A. Rodgers, X. Xu, G. Lin, S. Kumar, B.-Y. Nguyen, G.J. Hanna, C. Hwang, E. Martin, for the DRIVE-AHEAD Study Group, United States

Superior efficacy of dolutegravir (DTG) plus 2 nucleoside reverse transcriptase inhibitors (NRTIs) compared with lopinavir/ritonavir (LPV/RTV) plus 2 NRTIs in second-line treatment: interim data from the DAWNING study

M. Aboud, R. Kaplan, J. Lombaard, F. Zhang, J. Hidalgo, E. Mamedova, M. Losso, P. Chetchotisakd, J. Sievers, D. Brown, J. Hopking, M. Underwood, M.C. Nascimento, M. Gartland, K. Smith, United Kingdom

HIV-specific broadly-neutralizing monoclonal antibody, VRC01, minimally impacts time to viral rebound following treatment interruption in virologically-suppressed, HIV-infected participants who initiated antiretroviral therapy during acute HIV infection

T.A. Crowell, D.J. Colby, S. Pinyakorn, J. Intasan, K. Benjapornpong, K. Tanjinareel, N. Chomont, L. Trautmann, S. Tovanabutra, S. Krebs, D. Bolton, A. McDermott, R. Bailor, N. Doria-Rose, B. Patel, R.J. Gorelick, B.A. Fullmer, P. Visudhiphan, R.J. O'Connell, R. Tressler, J. Mascola, N.L. Michael, M.L. Robb, N. Phanuphak, J. Ananworanich, RV397 and RV254/SEARCH010 Study Groups
United States

TUAC04 Prevention: It's Not Just about PrEP

Oral Abstract Session

Venue: Blue Amphitheater

Time: 14:30-16:00

Co-Chairs: Jason Reed, Jhpiego, United States
Peter Godfrey-Faussett, UNAIDS, Switzerland

The effect of a conditional cash transfer for HIV prevention on the experience of partner violence for young women: evidence from a randomized experiment in South Africa HPTN 068

K. Kilburn, A. Pettifor, J. Edwards, A. Selin, S. Delong, R. Twine, J. Hughes, J. Wang, X. Gomez-Olive, C. MacPhail, K. Kahn
United States

The effect of school attendance and school drop out on incident HIV and HSV-2 among young women in rural South Africa enrolled in HPTN 068

M.C.D. Stoner, J.K. Edwards, W.C. Miller, A.E. Aiello, C.T. Halpern, A. Julien, A. Selin, R. Twine, J. Hughes, J. Wang, F.X. Gomez-Olive, R.W. Wagner, C. MacPhail, O. Laeyendecker, Y. Agyei, S.M. Tollman, K. Kahn, A. Pettifor, HPTN 068
United States

Increasing HIV test uptake and case finding through assisted HIV partner notification services: a systematic review and meta-analysis

S. Dalal, C. Johnson, V. Fonner, C. Kennedy, N. Siegfried, C. Figueroa, R. Baggaey
WHO

Association between HIV and sexually transmitted infections and partner circumcision among women in uMgungundlovu District, South Africa: a cross-sectional analysis of HIPSS baseline data

S. Davis, C. Toledo, L. Lewis, C. Cawood, A. Bere, M. Glenshaw, A. Kharsany
United States

Effects of syringe distribution policy change at a syringe services program in Baltimore, MD: a forecast analysis

S. Allen, J. Park, B. Weir, D. Holtgrave, S. Sherman
United States

Increasing knowledge of HIV status among men: a cluster-randomised trial of community-based distribution of oral HIV self-test kits nested in four HPTN 071 communities in Zambia

H. Ayles, S. Floyd, C. Mulubwa, B. Hensen, A. Schaap, M. Phiri, B. Chiti, K. Shanaube, M. Simwinda, V. Bond, S. Fidler, R. Hayes, A. Mwinga, on behalf of the HPTN 071 study team
United Kingdom

TUAC05 The Key to Key Populations

Oral Abstract Session

Venue: Bordeaux Amphitheater

Time: 14:30-16:00

Co-Chairs: Yves Yomb, Centre Alternatives Cameroon, Cameroon
Brenda Hoagland, Instituto de Pesquisa Clínica Evandro Chagas - IPEC/FIOCRUZ, Brazil

Are migrants acquiring HIV before or after migration to Spain? Results from the aMASE study

D. Alvarez-del Arco, J. del Romero, F. Pulido, M. Velasco Arribas, F. Dronda, J.R. Blanco, P. Garcia de Olalla, I. Ocaña, J. Belda Ibáñez, M.J. Barbera, S. Cuéllar, J. Iribarren, A. López-Liro, M. Masía, E. Fernández, G. Mateu, A. Peña, P. Ndumbi, J. del Amo, aMASE Study Group
Spain

Prevalence, trends and risk factors of transactional sex among men who have sex with men in metro Vancouver, Canada: a longitudinal event-level analysis

N.J. Lachowsky, L. Wang, J. Zhu, H. Armstrong, M. Taylor, G. Olarewaju, R. Hogg, E.A. Roth, D.M. Moore, Momentum Health Study
Canada

Is on-demand HIV pre-exposure prophylaxis (PrEP) a suitable tool for men who have sex with men (MSM) who participate in chemsex? Results from a sub-study of the ANRS-IPERGAY trial

P. Roux, L. Fressard, M. Suzan-Monti, J. Chas, C. Capitant, L. Meyer, C. Tremblay, J.-M. Molina, G. Pialoux, B. Spire, ANRS IPERGAY Study Group
France

Assessing HIV prevalence and health outcomes of children of female sex workers in Port Elizabeth, South Africa to guide PMTCT programming for vulnerable populations

S. Schwartz, Z. Kose, M. Mcingana, A. Rao, A. Lambert, V. Srivatsan, N. Phaswana-Mafuya, H. Hausler, S. Baral
United States

Low HIV incidence but high HCV incidence among people who inject drugs in Haiphong, Vietnam: results of the ANRS 12299/NIDA P30DA011041 DRIVE-IN study

M.K. Pham, J.P. Moles, H. Duong Thi, T. Nguyen Thi, G. Hoang Thi, T.T. Nham Thi, V. Vu Hai, H.O. Khuat Thi, R. Vallo, M. Peries, K. Arasteh, C. Quillet, J. Feelemyer, L. Michel, T. Hammett, N. Nagot, D. Des Jarlais, D. Laureillard, DRIVE study group
Vietnam

HIV treatment prevents HIV transmission in male serodiscordant couples in Australia, Thailand and Brazil

B. Bavinton, B. Grinsztejn, N. Phanuphak, F. Jin, I. Zablotska, G. Prestage, A. Kelleher, A. Pinto, D. Cooper, A. Grulich, The Opposites Attract Study Group
Australia

TUAD01 Treat All: How to Make It Happen and Can We Afford It?

Oral Abstract Session

Venue: Maillot Room

Time: 14:30-16:00

Co-Chairs: Gottfried Hirschall, World Health Organization (WHO), Switzerland
Salim Abdool Karim, Centre for the AIDS Programme of Research in South Africa (CAPRISA), South Africa

Introductory remarks

M. Wijnroks, The Global Fund to Fight AIDS, Tuberculosis and Malaria, Switzerland

Wide-ranging real-world impacts of a policy change on treatment eligibility on ART initiation and retention in care in Zambia

A. Mody, A. Zanolini, K. Sikombe, P. Somwe, I. Sikazwe, C. Bolton, C. Holmes, N. Padian, E. Geng
United States

Pre-ART peak and plateau: early lessons from Zimbabwe on operational impact of 'pre-ART mop-up' on ART initiation rates under Treat All

K. Webb, V. Chitiyo, P. Nesara, S. Page-Mtongwiza, J. Murungu, T. Maphosa, P. Mbetu, B. Engelsmann
Zimbabwe

Evaluating the feasibility of implementing UNAIDS' 90 90 90 strategy, achieving universal access to treatment and eliminating HIV in Malawi

S. Blower, L. Palk
United States

Generic treatments for HIV, HBV, HCV, TB could be mass produced for < \$90 per patient

A. Hill, M. Barber, D. Gotham, J. Fortunak, A. Pozniak
United Kingdom

Comparative analysis of ARV costs before and after the Clinical Protocol and Therapeutic Guidelines for the management of adult HIV infection (PCDT) was adopted in 2013 in Brazil

M.C. Pimenta, L. Hasenclever, C.F. Rocha, G. Cunha, A. Ana Pati Pascom, M. Freitas, R. Girade Corrêa, G.F. Mendes Pereira, C.J. Braga Batista, J. Monteiro da Cruz
Brazil

Index partner testing and targeted case finding in northern Haiti

V.A. Francois
Haiti

TUBS02 Microbiome

Bridging Session

Venue: Havana Amphitheater

Time: 14:30-16:00

Co-Chairs: Alan Landay, Rush University, United States
Elisabeth Menu, Pasteur Institute, France

With the development of new high throughput sequencing approaches, microbiota has become a major focal point of the scientific community, and increasing efforts are currently being made to better understand its influence on human health. Its study in the context of HIV infection is therefore of foremost importance. Microbial translocation is a major facet of HIV pathogenesis, associated with increased immune activation and potentially the onset of inflammation related comorbidities in HIV-positive patients. In this session, aimed at basic scientists and clinical researchers among others, we learn about the latest findings with regards to the role of the microbiome in HIV acquisition and pathogenesis, from animal models to potential therapeutic interventions in patients.

Introduction

E.Menu, Pasteur Institute, France

Global overview, beyond HIV

A.Landay, Rush University, United States

The vaginal microbiota: the first line of defense against HIV

J.Ravel, University of Maryland School of Medicine, United States

Microbiome in HIV animal models

J.Brenchley, Laboratory of parasitic diseases, NIAID, NIH, United States

Microbiome, FGT, and HIV acquisition

N.Klatt, University of Washington, United States

Review on clinical trials to improve the microbiome function

R.Kaul, University of Toronto, Canada

Questions and answers

Closing remarks

TUAD02 Decisions, Decisions, Decisions: Behavioural Economics

Oral Abstract Session

Venue: Blue Amphitheater

Time: 16:30-18:00

Co-Chairs: Jean-Paul Moatti, Institut de Recherche pour le Développement (IRD), France
Bruce Schackman, Cornell University, United States

Association between user fees and dropout from methadone maintenance therapy: results of a cohort study in Vietnam

*B. Johns, L.B. Chau, K.H. Hanh, N.D. Manh, H.M. Do, A.T. Duong, L.H. Nguyen
Vietnam*

A combination intervention strategy to enhance outcomes across the HIV care continuum and support epidemic control: data from a cluster-randomized trial in Mozambique

*B. Elul, M. Lamb, L. Ahoua, F. Abacassamo, S. Kujawski, M. Lahuerta
United States*

Economic evaluation of non-financial incentives to increase couples HIV testing and counselling uptake in Zimbabwe

*C. Mangenah, E. Sibanda, K. Hatzold, G. Maringwa, S. Gudukeya, N. Madiidi, O. Mugurungi, F. Terris-Prestholt, F. Cowan, H. Thirumurthy
Zimbabwe*

The effects of short-term cash and food incentives on food insecurity and labor force participation among HIV-infected adults initiating antiretroviral therapy in rural Tanzania

C. Fahey, P.F. Njau, N. Kapologwe, W.H. Dow, S.I. McCoy

United States

Using conjoint analysis to model hospital directors' decision making in adoption of an evidence-based stigma-reduction intervention

C. Lin, L. Li, S.-J. Lee, Z. Wu

United States

Willingness and ability of OST clients to pay for some OST services in Odesa region in the light of the Ukraine crisis

L. Khomych, O. Postnov, N. Avaliani, O. Iaremenko, M. Duda

Ukraine

TUBS03 Integrating Substance Abuse Treatment into HIV Services Across the Treatment Cascade

Bridging Session

Venue: Bordeaux Amphitheater

Time: 16:30-18:00

Co-Chairs: Adeeba Kamarulzaman, University of Malaya, Malaysia
Kate Thomson, The Global Fund to Fight AIDS, Tuberculosis and Malaria, Switzerland

Considering the realities of people who use drugs and their HIV service needs, this session looks at promising ways of integrating substance abuse treatment and HIV services across the cascade in order to optimize the health outcomes of people who use drugs. It is targeted towards clinicians, programme implementers and policy-makers. Participants will learn about various models of integrating substance abuse treatment in HIV services from different regions and trials and deepen their understanding of HIV service needs of people who use drugs.

Introduction

Harm reduction programmes in Ukraine: a client perspective

A.Basenka, Alliance for Public Health, Ukraine

Intervention of HIV, drug use, and the criminal justice system in Malaysia

F.Altice, Yale University, United States

Integrated models of addiction and HIV treatment in Vietnam

G.Le, Hanoi Medical University, Vietnam

Deadly trio: mental health – HIV - drugs

L.Michel, CSAPA Pierre Nicole, France

Questions and answers

Closing remarks

TUSY03 HIV and STIs: The Terrible Lovers

Symposia Session

Venue: Le Grand Amphithéâtre

Time: 16:30-18:00

Co-Chairs: Myron Cohen, UNC School of Medicine, United States
Adele Benzaken, Ministry of Health, Brazil

Increased rates of STIs have been reported in individuals at high risk of HIV acquisition. This symposium reviews the epidemiology of STIs over the last 50 years and in the era of antiretroviral use for HIV prevention, addresses the role of STIs in facilitating HIV acquisition, and discusses new strategies for STIs testing. In addition, this symposium reviews the emergence of antibiotic resistance and the current status of vaccine research for bacterial STIs.

Introduction

Epidemiology of STIs in the HIV and AIDS era

D.Russell, Cairns Sexual Health Service, Australia

STIs and susceptibility to HIV-infection

S.McClelland, University of Washington, United States

Testing strategies for STIs: where are we today?

C.Celum, University of Washington, United States

Should we fear antibiotic resistance for STIs?

C. Bébéar, Université de Bordeaux, France

Moderated discussion

Closing remarks

TUSY04 HIV and Hepatitis Co-infections in Adolescents and Women: Progress and Pitfalls

Symposia Session

Venue: Havana Amphitheater

Time: 16:30-18:00

Co-Chairs: Cristiana Oprea, Carol Davila University of Medicine and Pharmacy, Romania
Justyna Kowalska, EACS, Wave, Poland

This session focuses on some of the key issues facing the clinical management and engagement of women and adolescents, highlights some of the key current considerations for women living with HIV/HCV or HIV/HBV coinfection in particular with regard to perinatal transmission. Additionally, the session focuses on (1) the challenges in the clinical care of adolescents who were perinatally infected with HIV and (2) strategies to ensure that young people feel engaged in their healthcare. Highlighting examples from a number of countries including eastern Europe, the five presentations showcase progress and pitfalls and identify ways forward for improving the health and well-being of women and adolescents living with HIV and other co-morbidities in the region.

Introduction

Perinatal transmission of HBV and HCV in HIV-coinfected women: what are the risks and what can be done?

C. Thorne, University College London (UCL), United Kingdom

HIV management in adolescents: what are the challenges?

P. Rojo, Hospital 12 de Octubre, Complutense University, Spain

Providing youth friendly services to women and girls in Macedonia: how is it working?

M. Stevanovic, Health Education and Research Association (HERA), Macedonia, FYR

The role of civil society in scaling up access to Hepatitis C treatment in eastern Europe and Central Asia

L. Maistat, Medicines Patent Pool, Switzerland; L. Maistat, Medicines Patent Pool, Ukraine

Making the client and provider relationship work: what adolescents want and need?

M. Teov, Health Education and Research Association (HERA), Macedonia, FYR

Questions and answers

Closing remarks

J. Kowalska, EACS, Wave, Poland

TUSY05 Ending AIDS through Research Training and Capacity Building in Low- and Middle-income Countries: Lessons Learned and Future Directions

Symposia Session

Venue: Maillot Room

Time: 16:30-18:00

Co-Chairs: Peter Kilmarx, Forgarty International, NIH, United States
Quarraisha Abdool Karim, Centre for the AIDS Programme of Research in South Africa (CAPRISA), South Africa

Research training and institutional capacity building in low- and middle-income countries (LMICs) have been critical to advance our understanding of HIV and AIDS and identify novel approaches to prevention and treatment. A panel of senior HIV and AIDS research leaders from LMICs reflect on how their early research training enabled them to become leaders in the field and facilitate discoveries and development of drugs and best practices. As many research challenges remain, the discussion provides an opportunity for attendees to recommend priorities for supporting research training and institutional capacity building in LMICs in the future.

Introduction

Background

Q. Abdool Karim, Centre for the AIDS Programme of Research in South Africa (CAPRISA), South Africa; P. Kilmarx, Forgarty International, NIH, United States

Advances in care and treatment of AIDS, tuberculosis, and other opportunistic infections through research capacity building in Haiti

J. Pape, Les Centres Gheskio, Haiti

The early-career training springboard: from pipettes to programmes

L. Bekker, Desmond Tutu HIV Centre, South Africa

Transforming medical education to strengthen clinical care and research capacity in sub-Saharan Africa.

J. Hakim, University of Zimbabwe, Zimbabwe

The role of biomedical research training in HIV vaccine discovery

G. Gray, South African Medical Research Council, South Africa

The global benefits of building AIDS research capacity in South Africa: the case of HIV prevention in women

S. Abdool Karim, Centre for the AIDS Programme of Research in South Africa (CAPRISA), South Africa

Panel discussion

Closing remarks